BioMarin Pharmaceutical Inc., founded in 1997, is a US-based biotechnology company dedicated to developing and commercializing therapeutic enzyme products. The company's core mission is to translate genetic discoveries into innovative medicines that advance human health. BioMarin focuses on treating rare genetic diseases, particularly lysosomal storage disorders, and provides diagnostic services in carbohydrate biology. Their market focus includes patients with unmet medical needs, aiming to improve care and quality of life through their specialized therapies.

Notable figures affiliated with BioMarin include its co-founder Christopher Starr and key investors such as Baker Bros. Advisors. The company has achieved significant milestones, including the development of several FDA-approved treatments like Vimizim and Brineura. BioMarin's impact is profound in the rare disease community, offering hope and improved outcomes for patients with conditions previously lacking effective treatments. Their commitment to patient-centric solutions and pioneering science positions them as a leader in the biotech industry.